Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology.
Please direct podcast-related inquiries to [email protected].
Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
Please direct podcast-related inquiries to [email protected].
Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
- Update frequency
- every 5 days
- Average duration
- 21 minutes
- Episodes
- 160
- Years Active
- 2020 - 2025
Diabetes Dialogue: Inequities & Barriers in Diabetes, with Jasmine Gonzalvo, PharmD
In the third special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, Dr. Jasmine Gonzalvo, director of the Center for Health Equity and Innova…
00:11:13 |
Thu 09 Jun 2022
Diabetes Dialogue: Frontline Perspective from ADA 2022, with Gary Scheiner, MS, CDE
In our second special edition episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives from ADA 2022, hosts Drs. Diana Isaacs and Natalie Bellini are joined by Gary Scheiner,…
00:17:18 |
Thu 09 Jun 2022
Diabetes Dialogue: Optimizing CGM Uptake in Primary Care
In the first of 4 special edition ADA 2022 episodes, hosts Drs. Diana Isaacs and Natalie Bellini take on the role of interviewers and discuss CGM uptake in primary care with Drs. Sean and Tamara Oser…
00:20:16 |
Tue 07 Jun 2022
Diabetes Dialogue: Tirzepatide in Action & AACE 2022 Recap
In this episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take a deep dive into what the tirzepatide (Mounjaro) …
00:22:06 |
Fri 20 May 2022
Diabetes Dialogue: ATTD 2022 Recap
In this special edition ATTD Recap episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini…
00:20:33 |
Fri 06 May 2022
Diabetes Dialogue: April 2022
In the April 2022 edition of Diabetes Dialogue: Therapeutics, Technology, and Real-World Perspectives, hosts Drs. Diana Isaacs and Natalie Bellini discuss the implications of semaglutide 2.0 mg (Ozem…
00:19:29 |
Thu 28 Apr 2022
Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives
The inaugural episode of Diabetes Dialogue features an introduction to hosts Diana Isaacs, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP, and Natalie Bellini, DNP, FNP-BC, and a discussion around recent r…
00:22:47 |
Wed 30 Mar 2022
Semaglutide 2.4 mg (Wegovy):A Turning Point for Obesity
Ahead of ADA 2021, Dr. Thomas Wadden discusses the significance of the Wegovy approval for chronic weight management and Novo Nordisk's plans to evaluate an oral version.
00:16:09 |
Fri 25 Jun 2021
Subcutaneous Semaglutide for Weight Loss with Thomas Wadden, PhD
This episode of the Endocrine Outlook podcast features Thomas Wadden, PhD, a professor of psychology at Perelman School of Medicine at the University of Penn. Wadden is also a principal investigator …
00:24:06 |
Tue 16 Mar 2021
Tirzepatide for Weight Loss and Lowering HbA1c with Juan Frias, MD
This episode of the Endocrine Outlook features a conversation with Juan Frias, MD, medical director of the National Research Institute. Frias is also the principal investigator of the SURPASS-2 trial…
00:20:46 |
Mon 15 Mar 2021
Dietary Interventions and the Role of Nutrition in Obesity with Ariana Chao, PhD, CRNP
In this episode, Endocrinology Network senior editor Patrick Campbell speaks with Dr. Ariana Chao, of Penn Nursing, about dietary interventions and nutrition. Chao is the lead author of a recent stud…
00:18:24 |
Wed 17 Feb 2021
Jeffrey Curtis, MD: Osteoporosis in 2020
This episode of the Endocrine Outlook features a recent interview with Dr. Jeffrey Curtis, of the University of Alabama at Birmingham. A rheumatologist and leading expert in osteoporosis research, C…
00:20:39 |
Mon 07 Dec 2020
Osilodrostat and Treatment of Cushing's Disease
Dr. Georgiana Dobri, a neuroendocrinologist with Weill Cornell Medicine, discusses the approval of osilodrostat and management of Cushing's disease in 2020.
00:23:29 |
Fri 30 Oct 2020
Terri Lipman, PhD, CRNP: Addressing Racial Disparities in Medicine
This episode of the Endocrine Outlook features a conversation with Terri Lipman, PhD, CRNP, of the University of Pennsylvania. In the interview, Lipman discusses and offers perspective on a recent st…
00:20:21 |
Thu 29 Oct 2020
Raymond Douglas, MD, PhD: State of Thyroid Eye Disease in 2020
Raymond Douglas, MD, PhD, discusses trends in therapies and the current state of thyroid eye disease treatments in 2020.
00:18:14 |
Mon 19 Oct 2020
Muthiah Vaduganathan, MD: Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1 RAs
In this episode of the Endocrine Outlook, listeners will hear a conversation with Muthiah Vaduganathan, MD, MPH, a cardiologist at Brigham and Women’s hospital. Vaduganathan was also the member of th…
00:25:47 |
Thu 08 Oct 2020
Prof. Hiddo Heerspink: Insights from DAPA-CKD
In this special edition episode of the Endocrine Outlook, you will hear from Professor Hiddo Heerspink.
Heerspink recently presented results of the DAPA-CKD trial at the European Society of Cardiol…
00:12:11 |
Tue 01 Sep 2020
Joshua Denson, MD: Metabolic Syndrome and COVID-19 Outcomes
In this episode of the endocrine outlook, you will hear from Dr. Joshua Denson of Tulane University Medicine. In the episode, we discuss the results of a recent study he led examining the effects of …
00:19:24 |
Tue 01 Sep 2020
Robert Busch, MD: Topline Results of EMPEROR-REDUCED
In this episode we will be discussing reaction to topline results from the EMPEROR-REDUCED trial examining the use of empagliflozin for heart failure in patients with and without diabetes with endocr…
00:17:14 |
Fri 31 Jul 2020
Diabetes Research & COVID-19
In this episode you’ll hear my interview with Dr. Jamie Hartmann-Boyce, senior research fellow and departmental lecturer at the Nuffield Department of Primary Care Health Sciences of University of Ox…
00:22:08 |
Fri 31 Jul 2020
Disclaimer: The podcast and artwork embedded on this page are the property of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives. This content is not affiliated with or endorsed by eachpod.com.